Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31


Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.

Lee SJ, Yang A, Wu TC, Hung CF.

J Gynecol Oncol. 2016 Sep;27(5):e51. doi: 10.3802/jgo.2016.27.e51. Epub 2016 May 31. Review.


4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression.

Barsoumian HB, Yolcu ES, Shirwan H.

PLoS One. 2016 Apr 6;11(4):e0153088. doi: 10.1371/journal.pone.0153088. eCollection 2016.


SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer.

Srivastava AK, Yolcu ES, Dinc G, Sharma RK, Shirwan H.

Oncoimmunology. 2015 Jul 1;5(1):e1064580. eCollection 2016.


4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Bartkowiak T, Curran MA.

Front Oncol. 2015 Jun 8;5:117. doi: 10.3389/fonc.2015.00117. eCollection 2015. Review.


IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses.

Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, Dehlink E, Shade KT, Anthony RM, Blumberg RS, Turley SJ, Fiebiger E.

Cell Rep. 2015 Mar 3. pii: S2211-1247(15)00143-6. doi: 10.1016/j.celrep.2015.02.015. [Epub ahead of print]


SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.

Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H.

Cancer Res. 2014 Nov 15;74(22):6441-51. doi: 10.1158/0008-5472.CAN-14-1768-A. Epub 2014 Sep 24.


4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques.

Spencer AJ, Furze J, Honeycutt JD, Calvert A, Saurya S, Colloca S, Wyllie DH, Gilbert SC, Bregu M, Cottingham MG, Hill AV.

PLoS One. 2014 Aug 20;9(8):e105520. doi: 10.1371/journal.pone.0105520. eCollection 2014.


SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Sharma RK, Yolcu ES, Shirwan H.

Expert Rev Vaccines. 2014 Mar;13(3):387-98. doi: 10.1586/14760584.2014.880340. Review.


CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.

Sharma RK, Yolcu ES, Srivastava AK, Shirwan H.

PLoS One. 2013 Sep 16;8(9):e73145. doi: 10.1371/journal.pone.0073145. eCollection 2013.


Expression of leukotriene B₄ receptor-1 on CD8⁺ T cells is required for their migration into tumors to elicit effective antitumor immunity.

Sharma RK, Chheda Z, Jala VR, Haribabu B.

J Immunol. 2013 Sep 15;191(6):3462-70. doi: 10.4049/jimmunol.1300967. Epub 2013 Aug 19.


Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model.

Nguyen CT, Hong SH, Ung TT, Verma V, Kim SY, Rhee JH, Lee SE.

Clin Exp Vaccine Res. 2013 Jul;2(2):128-34. doi: 10.7774/cevr.2013.2.2.128. Epub 2013 Jul 3.


The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

Moran AE, Kovacsovics-Bankowski M, Weinberg AD.

Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14. Review.


Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.

Youlin K, Li Z, Xin G, Mingchao X, Xiuheng L, Xiaodong W.

Hum Vaccin Immunother. 2013 Apr;9(4):766-72. doi: 10.4161/hv.23116. Epub 2013 Jan 7.


Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model.

Miguel A, Herrero MJ, Sendra L, Botella R, Algás R, Sánchez M, Aliño SF.

Toxins (Basel). 2012 Oct 31;4(11):1058-81. doi: 10.3390/toxins4111058.


Emerging human papillomavirus vaccines.

Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC.

Expert Opin Emerg Drugs. 2012 Dec;17(4):469-92. doi: 10.1517/14728214.2012.744393. Epub 2012 Nov 19. Review.


Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.

Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, Shirwan H.

PLoS One. 2012;7(11):e48463. doi: 10.1371/journal.pone.0048463. Epub 2012 Nov 8.


Targeted treatments for cervical cancer: a review.

Peralta-Zaragoza O, Bermúdez-Morales VH, Pérez-Plasencia C, Salazar-León J, Gómez-Cerón C, Madrid-Marina V.

Onco Targets Ther. 2012;5:315-28. doi: 10.2147/OTT.S25123. Epub 2012 Nov 2.


Enhanced antitumor effects of a dendritic cell vaccine transfected with gastric cancer cell total RNA carrying the 4-1BBL gene in vitro.

Song Z, Guo C, Li Y, Tan B, Fan L, Xiao J.

Exp Ther Med. 2012 Feb;3(2):319-323. Epub 2011 Nov 28.


SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.

Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H.

PLoS One. 2012;7(8):e42459. doi: 10.1371/journal.pone.0042459. Epub 2012 Aug 1. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/88b557df-1e27-4a60-8b47-214a5cc3c707.

Supplemental Content

Support Center